Trials of the elimination of the central effects of Ronpacon Cerebral 280 after its administration into the cerebral lateral ventricle in rats.
D000818:Animals; D014695:Cerebral Ventriculography / Q000009:adverse effects*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D003975:Diazepam / Q000627:therapeutic use; D004336:Drug Antagonism; D005260:Female; D005984:Glutethimide / Q000627:therapeutic use; D007276:Injections, Intraventricular; D008297:Male; D008620:Meprobamate / Q000627:therapeutic use; D009930:Organic Chemicals; D010634:Phenobarbital / Q000627:therapeutic use; D051381:Rats; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*
D003287:Contrast Media; D009930:Organic Chemicals; C024945:Ronpacon Cerebral 280; D008620:Meprobamate; D005984:Glutethimide; D003975:Diazepam; D010634:Phenobarbital